tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Aligos Therapeutics presents data from eight presentations at AASLD
PremiumThe FlyAligos Therapeutics presents data from eight presentations at AASLD
1M ago
Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating
Premium
Ratings
Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating
1M ago
Aligos Therapeutics Reports Q3 2025 Progress and Financials
Premium
Company Announcements
Aligos Therapeutics Reports Q3 2025 Progress and Financials
2M ago
Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
PremiumRatingsPositive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
3M ago
Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target
Premium
Ratings
Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target
3M ago
Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs
Premium
The Fly
Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs
4M ago
Aligos Therapeutics Reports Q2 2025 Progress and Results
PremiumCompany AnnouncementsAligos Therapeutics Reports Q2 2025 Progress and Results
5M ago
Aligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)
Premium
The Fly
Aligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)
5M ago
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
Premium
The Fly
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100